In this study, compared with patients with chronic back pain (CBP), the level of serum anti-CD74 IgG autoantibody did not elevate in early axSpA patients, and the difference in prevalence of anti-CD74 IgG autoantibody in axSpA and CBP patients was not significant (46.4, 47.9%, respectively). The gene discussed is CD74; the disease is red color blindness.